证券记录 · 已归档季度
CLDX
Celldex Therapeutics, Inc. · Healthcare · Biotechnology
12被追踪持有人
+1Δ持有人
21.78M持有股份
$550.46M报告持仓市值
+2新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 +9.1% ·
股份流向 +4.1% ·
净新建仓位 +8.3%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q4 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +8 | 50.70M | $1.89B | +11 | −3 |
| Q1 2026 | 82 | +10 | 42.54M | $1.35B | +12 | −2 |
| Q4 2025 | 72 | 0 | 42.78M | $1.16B | — | — |
| Q3 2025 | 17 | 0 | 35.45M | $917.00M | — | — |
| Q2 2025 | 14 | 0 | 33.46M | $680.97M | — | — |
| Q1 2025 | 11 | -1 | 21.24M | $385.48M | — | −1 |
| Q4 2024 | 12 | +1 | 21.78M | $550.46M | +2 | −1 |
| Q3 2024 | 10 | -1 | 17.69M | $601.30M | — | −1 |
| Q2 2024 | 11 | — | 17.48M | $646.94M | — | — |
持有人 · Q4 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 8.98M | -2.9% | $226.82M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 3.56M | +23.5% | $89.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 3.56M | +23.5% | $89.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | State Street Global Advisors ✦ (被动) | 3.23M | — | $81.75M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 2.52M | +60.4% | $63.58M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 12 | Geode Capital Management ✦ (被动) | 1.53M | -0.4% | $38.80M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Geode Capital Management ✦ (被动) | 1.53M | -0.4% | $38.80M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 708.09K | -16.4% | $17.89M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 708.09K | -16.4% | $17.89M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 518.34K | -37.2% | $13.10M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 518.34K | -37.2% | $13.10M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 452.50K | +20.9% | $11.43M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 136.59K | 新增 | $3.45M | 0.0% | New | 1 | SEC ↗ |
| 20 | Millennium Management ✦ | 93.60K | -13.4% | $2.37M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 33.02K | 新增 | $834,542 | 0.0% | New | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 21.72K | -14.3% | $548,965 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 21.72K | -14.3% | $548,965 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Renaissance Technologies | $3.45M | 0.0% |
| Two Sigma Investments | $834,542 | 0.0% |
已清仓
| Marshall Wace | $9.41M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 227 持有人, 72.32M 股份, $2.21B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q4 2024 ·
方法论 ·
通过API获取此数据